Glenmark Pharma gets nod to launch favipiravir for Covid-19 patients

Glenmark is conducting phase-3 clinical trials; drug has got restricted emergency use

Antiviral oral drug favipiravir on Friday received the nod from the Indian drug regulator to be launched in the domestic market to treat mild-to-moderate patients of Covid-19. 

Mumbai-based drug major Glenmark Pharmaceuticals is conducting phase-III clinical trials to assess the drug’s efficacy on Covid-19 patients. The drug may be available as early as next week, claimed sources. 

India had given nod to Gilead’s remdesivir some time back based on the clinical trial data presented by the company. 

The Drug Controller General of India (DCGI) has given manufacturing and marketing approval to Glenmark to launch oral favipiravir (under brand name FabiFlu) to treat mild